Methods for Using Low-Dose Colchicine After Myocardial Infarction (EP3821909A1)
Summary
The European Patent Office published application EP3821909A1, titled 'Methods for Using Low-Dose Colchicine After Myocardial Infarction.' The application, filed by Institut de Cardiologie de Montréal, claims methods of treating patients with low-dose colchicine following myocardial infarction. The published application covers 38 designated European states.
What changed
The EPO published European patent application EP3821909A1, claiming methods for administering low-dose colchicine to patients following myocardial infarction. The application, filed by Institut de Cardiologie de Montréal with inventor Jean-Claude Tardif, covers therapeutic uses of colchicine for cardiovascular indications.\n\nPharmaceutical companies developing anti-inflammatory cardiovascular therapies should monitor this application's progress toward grant. The patent, once granted, will provide exclusive rights across designated European states, potentially affecting freedom-to-operate for competing colchicine-based treatments.
What to do next
- Monitor for patent grant proceedings
- Review freedom-to-operate for colchicine-based cardiovascular treatments
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR USING LOW-DOSE COLCHICINE AFTER MYOCARIAL INFARCTION
Publication EP3821909A1 Kind: A1 Apr 08, 2026
Applicants
Institut de Cardiologie de Montréal
Inventors
TARDIF, Jean-Claude
IPC Classifications
A61K 45/06 20060101AFI20200616BHEP A61K 31/138 20060101ALI20200616BHEP A61P 11/00 20060101ALI20200616BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.